איקסמפרה 15 מ"ג

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

IXABEPILONE 15 MG

Commercializzato da:

BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED

Codice ATC:

L01DC04

Forma farmaceutica:

POWDER FOR CONCENTRATE FOR INFUSION

Via di somministrazione:

I.V

Prodotto da:

CORDEN PHARMA LATINA S.P.A., ITALY

Gruppo terapeutico:

IXABEPILONE

Indicazioni terapeutiche:

Ixempra is indicated for the treatment of inoperable locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy:In combination with capecitabine in patients failing prior therapy with a taxane and an anthracycline or for whom further anthracycline therapy is not indicated.As monotherapy in patients failing prior therapy with taxanes, capecitabine and anthracyclines or for whom futher anthracycline therapy is not indicated.

Data dell'autorizzazione:

2012-01-01